Management of adverse events in patients with HER2+metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)

T. -W Park-Simon,A. Okines,E. Paplomata,T. Wahl,G. Wright,S. Sutherland,E. Jakobsen, F. Valdes-Albini,A. Chan,A. S. Clark,A. Conlin,M. Lustberg,J. Specht,T. Pluard,X. Zhu,I Krop,K. Gelmon,D. Slamon,J. Ramos,W. Feng, E. Hamilton

JOURNAL OF CLINICAL ONCOLOGY（2021）

Cited 1|Views77

No score

Abstract

1043Background: Tucatinib (TUC) is an investigational TKI, highly selective for HER2 without significant inhibition of EGFR. HER2CLIMB is a randomized trial of TUC vs placebo in combination with tr...

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined